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Abstract
Introduction: In our previous studies we demonstrated that CXC chemokine receptor 3 (CXCR3) participates in the
regulation of lymphocyte trafficking during cecal ligation and puncture (CLP)-induced sepsis. In this study, we
evaluated the effects of treatment with anti-CXCR3 immunoglobulin (IgG) and antibiotics on outcome during
septic shock caused by CLP.
Methods: C57BL/6J mice were treated with neutralizing IgG against CXCR3 plus Primaxin either 24 hours prior to,
2 hours after or 6 hours after CLP. Control mice received nonspecific IgG plus Primaxin in the same regimen.
Survival, core body temperature, bacterial clearance and systemic cytokine production were evaluated.
Results: Our results show that treatment with anti-CXCR3 IgG plus Primaxin significantly improved survival when
administered 24 hours prior to CLP (50% vs. 10%), 2 hours after CLP (55% vs. 10%) or 6 hours after CLP (55% vs.
25%) compared with mice receiving nonspecific IgG plus Primaxin. Treatment with anti-CXCR3 plus Primaxin 24
hours prior to CLP attenuated hypothermia and IL-6 and macrophage inflammatory protein 2 (MIP-2) production
but did not alter bacterial clearance. Treatment with anti-CXCR3 IgG and Primaxin 2 hours after CLP did not
improve bacterial clearance and systemic cytokine production compared with mice treated with IgG and Primaxin,
whereas 6 hours after CLP the bacterial clearance and IL-6 and MIP-2 concentrations, both in plasma and
peritoneal lavage fluid, were significantly improved in mice receiving anti-CXCR3 IgG and Primaxin compared with
mice that only received nonspecific IgG and Primaxin.
Conclusion: The results from this study indicate that neutralization of CXCR3 prior to, 2 hours after or 6 hours after
the initiation of CLP-induced septic shock improves survival and attenuates CLP-induced inflammation and
physiologic dysfunction.
Introduction
CXC chemokine receptor 3 (CXCR3) is a G-protein
coupled chemokine receptor that is activated by the CXC
chemokine ligands CXCL9 (monokine induced by IFNg),
CXCL10 (interferon-inducible protein 10) and CXCL11
(interferon-inducible T-cell alpha chemoattractant) [1,2].
The CXCR3 ligands are produced by several cell types,
primarily in response to type I interferons (IFNa/b) and
IFNg [1,3,4]. CXCR3 is an important regulator of natural
killer (NK) lymphocyte, NK T lymphocyte and T-helper
type 1 (Th1) lymphocyte trafficking in response to viral
infection, allotransplantation, cancer and autoimmune
diseases [4-11]. The CXCR3 ligands act redundantly or
additively to regulate lymphocyte trafficking, depending
on the disease process and tissue under study [1]. More
recently, evidence has emerged that supports a role for
CXCR3 activation in the pathogenesis of sepsis. High
levels of CXCL10 have been observed in the plasma of
septic patients, and plasma CXCL10 concentrations have
been shown to parallel the severity of sepsis in humans
[12,13]. Punyadeera and colleagues showed that increas-
ing plasma CXCL10 concentrations were predictive of
progression from sepsis to septic shock in critically ill
patients [13]. In other clinical studies, plasma CXCL10
concentrations have been shown predictive of neonatal
sepsis and systemic infection in infants with high sensi-
tivity and specificity [14,15].
Our recent studies show that CXCR3 is an important
regulator of NK cell trafficking during severe sepsis
caused by cecal ligation and puncture (CLP) [16,17].
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High concentrations of CXCL9 and CXCL10 were mea-
sured in peritoneal lavage fluid and plasma in the first 8
hours after CLP, and a gradient was noted such that
CXCL9 and CXCL10 concentrations were higher in
peritoneal lavage fluid than in plasma. In parallel, large
numbers of CXCR3+ NK cells were found to leave the
spleen and blood prior to appearing in the peritoneal
cavity, a phenomenon that was ablated in CXCR3-defi-
cient mice and in mice treated with anti-CXCR3 IgG
[16]. Peak NK cell recruitment was noted to occur
between 8 and 16 hours after CLP. CXCR3 was also
expressed by large numbers (>90%) of NK T cells and a
subset of T lymphocytes, but those cell populations did
not exhibit trafficking to the site of infection during the
initial 8 to 16 hours after CLP. Compared with wildtype
control mice, survival is improved in septic CXCR3-defi-
cient mice and is associated with decreased systemic
cytokine production and attenuated development of
hypothermia [16]. The numbers of bacteria in peritoneal
lavage fluid, blood and the lung were not generally dif-
ferent in CXCR3-deficent mice compared with controls.
The improved outcomes observed in mice with CXCR3
deficiency therefore appear to be caused by attenuation
of systemic inflammation and organ dysfunction.
Our previous studies examined outcome, systemic
inflammation and bacterial clearance in CXCR3 knock-
out mice and in mice treated with anti-CXCR3 immuno-
globulin prior to the initiation of sepsis. In the present
study, the effect of CXCR3 blockade, when administered
after the initiation of sepsis, was investigated. The goal of
the study was to determine whether administration of
anti-CXCR3 IgG after the initiation of sepsis will attenu-
ate the pathobiology of sepsis and improve survival com-
pared with mice treated with nonspecific IgG.
Materials and methods
Mice
C57BL/6J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). Mice were utilized
in studies at 10 to 12 weeks of age. All studies were
approved by the Institutional Animal Care and Use
Committee at the University of Texas Medical Branch
and complied with the National Institutes of Health
Guide for the Care and Use of Experimental Animals.
Cecal ligation and puncture
CLP was performed as described previously [16]. Briefly,
mice were anesthetized with 2 to 3% isoflurane in oxygen.
After shaving and aseptic preparation of the surgical site,
a 1 to 2 cm midline incision was made through the
abdominal wall; the cecum was identified and ligated
with a 3-0 silk tie 1 cm from the tip. A double puncture
of the cecal wall was performed with a 20-gauge needle.
The incision was closed with Autoclips (Becton
Dickinson, Sparks, MD, USA). Mice received intraperito-
neal injection with 1 ml lactated Ringer’s solution con-
taining Primaxin (imipenem, a thienamycin antibiotic
and cilistatin, an inhibitor of the renal dipeptidase, dehy-
dropeptidase, 25 mg/kg; Merck & Co, Whitehouse Sta-
tion, NJ, USA) at the time of CLP, 2 hours after CLP or
6 hours after CLP. In post-treatment experiments, mice
received intravenous injection (0.1 ml) with either anti-
CXCR3 IgG (clone CXCR3-173, 100 μg; eBioscience, San
Diego, CA, USA) or isotype-matched, nonspecific IgG
(100 μg; eBioscience) 2 hours or 6 hours after CLP.
In pretreatment experiments, mice were treated with
anti-CXCR3 IgG or nonspecific IgG 24 hours prior to
CLP. All mice received buprenorphene (2.5 μg subcuta-
neously) 30 minutes before surgery and every 8 to
12 hours thereafter for analgesia. In survival studies, mice
were observed over a 2-week period. Rectal temperature,
cytokine concentrations and bacterial counts were per-
formed on samples collected 18 hours after CLP.
ELISA analysis
Heparinized blood was obtained by carotid laceration and
plasma was harvested from centrifuged blood (2,000×g for
15 minutes). Lavage of the peritoneal cavity was performed
with 3 ml sterile PBS. The IL-6 and macrophage inflam-
matory protein 2 (MIP-2) concentrations in peritoneal
lavage fluid and plasma were measured using an ELISA
according to the manufacturer’s protocol (eBioscience;
and R&D Systems, Minneapolis, MN, USA). Cytokine
concentrations were determined by measuring optical
density at 450 nm using a microtiter plate reader (Dyna-
tech Laboratories, Chantilly, VA, USA). Previous studies
from our laboratory, and others, show that the magnitude
of systemic IL-6 and MIP-2 production during CLP-
induced sepsis parallels the severity of physiologic dys-
function and mortality [16,17].
Measurement of temperature and bacterial counts
Body temperature was measured by insertion of a rectal
temperature probe immediately after induction of anesthe-
sia with 2 to 3% isoflurane in oxygen. Previous studies
from our laboratory, and others, show that the degree of
hypothermia during CLP-induced sepsis parallels the sever-
ity of physiologic dysfunction and mortality [16,17]. Bacter-
ial counts were performed on blood, peritoneal lavage fluid
and the lung. Samples of plasma and peritoneal lavage fluid
were obtained as described above. Lung tissue was har-
vested by thoracotomy under aseptic conditions, weighed
and homogenized in sterile PBS to achieve a final concen-
tration of 11 mg tissue per milliliter of saline. Samples
were serially diluted in sterile saline and cultured on tryptic
soy agar pour plates. Plates were incubated (37°C) for 24 to
48 hours and colony counts were performed by direct
visualization.
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Statistical analysis
All data were analyzed using GraphPad Prism software
(GraphPad, San Diego, CA, USA). Data from multiple
group experiments were analyzed using one-way analysis
of variance followed by a post hoc Tukey’s test to compare
groups. Paired data were analyzed using a paired t test.
For measurements of bacterial colony-forming, groups
were compared using a nonparametric Kruskal-Wallis test
followed by a post hoc Dunn’s test. Survival data were ana-
lyzed using the log-rank test. P < 0.05 was considered sta-
tistically significant for all experiments. All values are
presented as the mean ± standard error of the mean,
except for bacterial counts, for which median values are
designated.
Results
Treatment with anti-CXCR3 after CLP improves survival
and attenuates sepsis-induced hypothermia
Treatment with anti-CXCR3 IgG significantly improved
survival when administered 24 hours prior to (50% vs.
10%), 2 hours after (55% vs. 10%) or 6 hours after (55% vs.
25%) CLP compared with mice treated with nonspecific
IgG (Figure 1). All mice that survived beyond the 7-day
time point were alive and did not show signs of morbidity
2 weeks after CLP.
The development of hypothermia is a predictor of sepsis-
induced physiologic dysfunction in mice [16]. Rectal tem-
perature was significantly lower in all mice that underwent
the CLP procedure and were treated with nonspecific IgG
compared with control nonseptic mice (Figure 2). Rectal
temperature was significantly higher in mice treated with
anti-CXCR3 IgG compared with mice treated with nonspe-
cific IgG, regardless of whether treatment was initiated 24
hours before or 2 to 6 hours after CLP (Figure 2).
Effect of anti-CXCR3 treatment on bacterial burden
Mice were treated with Primaxin at the time of CLP or
at the time of anti-CXCR3 administration in cases
where a post-treatment protocol was used. Treatment of
mice with Primaxin decreased bacterial counts in the
blood, peritoneal cavity and lung by >99% compared
with control septic mice that did not receive antibiotic
treatment (Figure 3). Bacterial counts after treatment
with anti-CXCR3 IgG and Primaxin were not signifi-
cantly different from those in mice treated with nonspe-
cific IgG and Primaxin, except in the 6-hour post-
treatment group where a small but statistically signifi-
cant decrease in bacterial counts was observed in the
blood, peritoneal cavity and lung (Figure 3).
Effect of anti-CXCR3 treatment on proinflammatory
cytokine production
Treatment of mice with anti-CXCR3 IgG 24 hours prior to
CLP caused significant attenuation of IL-6 and MIP-2 con-
centrations in the blood and peritoneal lavage fluid com-
pared with mice treated with nonspecific IgG (Figure 4). In
the 2-hour and 6-hour post-treatment groups, IL-6 con-
centrations were significantly lower in the peritoneal lavage
fluid from anti-CXCR3-treated mice than in mice treated
with nonspecific IgG. A trend toward lower IL-6 concen-
trations was also observed in plasma from mice receiving
treatment with anti-CXCR3 2 or 6 hours after CLP but the
differences were not statistically significant. Concentrations
of MIP-2 in the peritoneal lavage fluid and plasma were
significantly lower in mice treated with anti-CXCR3 IgG 24
hours prior to CLP, but were not significantly different
when comparing mice treated with anti-CXCR3 IgG
2 hours after CLP compared with those treated with non-
specific IgG (Figure 4). In the 6-hour post-treatment
group, plasma and intraperitoneal IL-6 concentrations
were significantly lower in mice treated with anti-CXCR3
IgG than in those treated with nonspecific IgG (Figure 4).
Discussion
The present study shows that initiation of CXCR3
blockade, in combination with a broad-spectrum
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Figure 1 Treatment with anti-CXCR IgG improves survival during cecal ligation and puncture-induced sepsis. Mice were treated with
anti-CXC chemokine receptor 3 (anti-CXCR3) IgG (100 μg) or nonspecific IgG (100 μg) 24 hours prior to (n = 10 mice per group), 2 hours after
(n = 20 mice per group) or 6 hours after (n = 20 mice per group) cecal ligation and puncture (CLP). Mice were followed for survival over a 2-
week period. *P <0.05 compared with nonspecific IgG.
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Figure 2 Effect of anti-CXCR3 IgG treatment on core temperature. Mice were treated with anti-CXC chemokine receptor 3 (anti-CXCR3) IgG
(100 μg) or nonspecific IgG (100 μg) 24 hours prior to (n = 10 mice per group), 2 hours after (n = 10 mice per group) or 6 hours after (n = 13
mice per group) cecal ligation and puncture (CLP). Rectal temperature was measured 18 hours after CLP. Mice designated as control represent
nonseptic mice. *P <0.05 compared with nonspecific IgG, +P <0.05 compared with control.









































































































































Figure 3 Effect of anti-CXCR3 IgG treatment on bacterial burden. Mice were treated with anti-CXC chemokine receptor 3 (anti-CXCR3) IgG
(100 μg) or nonspecific IgG (100 μg) 24 hours prior to, 2 hours after or 6 hours after cecal ligation and puncture (CLP). Blood and peritoneal
lavage fluid were collected 18 hours after CLP and bacterial colony-forming units (CFU) were measured. Mice designated as control represent
septic mice that did not receive antibiotic treatment. n = 10 to 13 mice per group. *P <0.05 compared with nonspecific IgG, +P <0.05 compared
with control.
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antibiotic, 2 hours or 6 hours after CLP provides a sig-
nificant survival benefit compared with antibiotic treat-
ment alone. Our previous studies examined outcome,
systemic inflammation and bacterial clearance in
CXCR3 knockout mice and in mice treated with anti-
CXCR3 immunoglobulin prior to the initiation of sepsis.
The findings of the present study extend our previous
observations by showing the potential of CXCR3 block-
ade as a therapeutic approach to decrease the severity of
sepsis during its acute phase. The survival benefit
observed in mice treated with anti-CXCR3 IgG 2 hours
or 6 hours after the initiation of severe sepsis was simi-
lar to that seen in mice treated with anti-CXCR3
24 hours prior to CLP and was associated with attenua-
tion of sepsis-induced hypothermia and systemic cyto-
kine production. Bacterial clearance was not markedly
affected by CXCR3 blockade. Significant differences in
bacterial colony-forming units were not observed at
most time points evaluated in this study. However, a
small, but statistically significant, difference in bacterial
colony-forming units was observed in mice treated with
anti-CXCR3 IgG 6 hours after CLP. Yet the difference



































































































Figure 4 Effect of anti-CXCR3 IgG treatment on cytokine production. Mice were treated with anti-CXC chemokine receptor 3 (anti-CXCR3)
IgG (100 µg) or nonspecific IgG (100 µg) 24 hours prior to (n = 10 mice per group), 2 hours after (n = 10 mice per group) or 6 hours after (n =
13 mice per group) cecal ligation and puncture (CLP). Plasma and peritoneal lavage fluid were harvested 18 hours after CLP for measurement of
IL-6 and macrophage inflammatory protein 2 (MIP-2) concentrations by ELISA. *P <0.05 compared with nonspecific IgG.
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in bacterial burden in the 6-hour post-treatment group
was not associated with major differences in survival,
core temperature or systemic cytokine production com-
pared with mice treated with anti-CXCR3 IgG 24 hours
before or 2 hours after CLP. The beneficial effects of
CXCR3 blockade therefore do not appear to be depen-
dent on augmentation of bacterial clearance mechanisms.
Few studies have examined the effects of CXCR3 block-
ade during sepsis. Most prior efforts aimed at targeting
CXCR3 for therapeutic benefit have focused on chronic
autoimmune diseases such as multiple sclerosis, inflam-
matory bowel disease and rheumatoid arthritis [5,18-20].
Other investigators have shown that CXCR3 blockade is
beneficial in prolonging allograft survival in experimental
models of organ transplantation [21]. Most early studies
employed blocking antibodies against CXCR3 or its
ligands as the primary strategy to antagonize CXCR3.
More recent research has resulted in the development of
nonpeptidergic, small molecular weight CXCR3 inhibi-
tors [22-25]. The (aza)quinazolinone class of CXCR3
antagonists are the most promising, with AMG487 being
the most extensively developed [22]. AMG487 has been
shown to decrease T-cell migration and attenuate disease
severity in experimental models of pulmonary fibrosis
and collagen-induced arthritis [22]. Clinical trials showed
that AMG487 was relatively well tolerated but did not
have efficacy in patients with psoriasis. Studies are cur-
rently underway to modify the structure of AMG487 to
decrease drug metabolism and minimize drug accumula-
tion in humans. Whether nonpeptidergic CXCR3 inhibi-
tors are efficacious in experimental models of sepsis
remains to be determined. However, the present study
shows that antibody-based CXCR3 blocking approaches
are effective in the CLP model of septic shock and opens
the possibility that other blocking strategies may be
efficacious.
CXCR3 is expressed predominantly by NK lymphocytes,
NK T lymphocytes and Th1 lymphocytes. Previous studies
have shown that Th1 lymphocytes play an important role
in the pathogenesis of chronic autoimmune diseases
[26-28]. The effects of CXCR3 blockade in autoimmune
diseases are therefore probably mediated through inhibi-
tion of Th1 lymphocyte trafficking to sites of chronic
inflammation. However, our previous studies show that
trafficking of CXCR3+ T lymphocytes into the peritoneal
cavity is minimal in the initial 16 hours after CLP and that
CXCR3 deficiency or blockade does not alter T-cell
trafficking into the primary site of infection during CLP-
induced sepsis [16]. Likewise, we reported that the num-
bers of intraperitoneal CXCR3+ NK T cells did not change
during the course of CLP-induced septic shock. Yet large
numbers of CXCR3+ NK cells were found to migrate into
the peritoneal cavity within 4 to 8 hours after CLP. The
entry of CXCR3+ NK cells into the peritoneal cavity
paralleled a decline in splenic and blood NK cell numbers,
and both alterations were ablated in CXCR3-deficient
mice and in mice treated with anti-CXCR3 IgG. The traf-
ficking of NK cells into the infected and inflamed perito-
neal cavity coincided with elevations in CXCL9 and
CXCL10 concentrations, with CXCR3 ligand concentra-
tions being higher in the inflamed peritoneal cavity than in
plasma. CXCR3-deficient mice and mice treated with anti-
CXCR3 IgG showed improved survival, decreased systemic
cytokine production and attenuated physiologic dysfunc-
tion compared with control mice. These observations
imply that CXCR3-directed NK cell trafficking contributes
to the pathogenesis of septic shock. At this point, however,
that relationship is associative. Further work is needed to
fully define how CXCR3 is activated and mediates inflam-
matory and physiological changes during severe sepsis.
NK cells and NK T cells are known to contribute to
systemic inflammation and physiologic dysfunction dur-
ing sepsis and polytrauma [17,29-31]. However, the
mechanisms by which CXCR3 alters NK cell and NK
T-cell function during sepsis and the systemic inflam-
matory response syndrome is not completely under-
stood. NK cells do not uniformly express CXCR3. The
proportion of CXCR3+ NK cells varies between 20 and
60% in various tissues, with the peritoneal cavity, spleen,
bone marrow, lung and liver representing the major NK
cell-containing organs [32]. Murine CXCR3+ NK cells
have significant migratory potential and the capacity to
secrete IFNg and TNFa. In that regard, they are func-
tionally similar to human CD56bright NK cells. Like
human CD56dim NK cells, mouse CXCR3- NK cells have
low migratory potential, express high levels of CD11b,
possess significant cytotoxic activity and secrete less
IFNg and TNFa compared with CXCR3+ NK cells.
Interestingly, our previous studies show that not all
CXCR3+ NK cells migrate to the site of infection after
CLP [16]. A subset of CXCR3+ NK cells remains in the
spleen. In addition, large numbers of CXCR3+ NK cells
are present within the liver, lung and bone marrow and
their numbers do not change significantly during CLP-
induced sepsis. Our previous studies show that CXCR3
expression by hepatic NK cells decreases within 4 hours
of CLP and continues to decline during the first 16 hours
[16]. Likewise, the numbers of hepatic NK T cells, of
which >90% are CXCR3+, do not change after CLP but
CXCR3 expression by hepatic NK T cells declines after
CLP in a pattern similar to that observed for liver NK
cells [16]. The activation of NK cells and NK T cells is
known to cause internalization and downregulation of
CXCR3 [2]. Hepatic CXCR3+ NK cells and NK T cells
are therefore likely to become activated during CLP-
induced sepsis but do not migrate out of the liver. The
activation of NK T cells after CLP may facilitate intrahe-
patic trafficking since previous studies have shown that
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activation of CXCR3 functions to regulate the migration
of NK T cells within the hepatic sinusoids during periods
of bacterial infection [33]. However, whether hepatic NK
cells and NK T cells contribute to systemic inflammation
and physiologic dysfunction during septic shock and
whether CXCR3 contributes to the activation of those
cell populations remain to be determined.
Conclusions
This study shows that inhibition of CXCR3 activation
using blocking antibodies is efficacious in reducing the
severity of CLP-induced sepsis. Treatment with anti-
CXCR3 IgG was effective in prolonging survival when
administered up to 6 hours after CLP. The beneficial
effect is primarily associated with decreased systemic
cytokine production and attenuated physiologic dys-
function and appears to be independent of bacterial
clearance mechanisms. Further studies are needed to
fully define the protective mechanisms of CXCR3
blockade during sepsis and to determine its value as an
approach to limit injury and improve outcome during
sepsis.
Key message
• Treatment with anti-CXCR3 IgG up to 6 hours
after CLP will decrease systemic cytokine produc-
tion, attenuate physiologic dysfunction and improve
survival in a clinically relevant experimental model
of severe sepsis.
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